European RWE Solutions Market (2026-2036)

The European real-world evidence (RWE) solutions market was valued at USD 0.76 billion in 2025. It is expected to reach USD 0.84 billion in 2026 and is projected to grow to around USD 2.5 billion by 2036, at a CAGR of 11.4% during the forecast period from 2026 to 2036.

The growth of the European RWE solutions market is driven by increasing regulatory mandates for real-world evidence under the EU HTA Regulation, rising pharmaceutical R&D activity, growing adoption of electronic health records across European health systems, and the progressive implementation of the European Health Data Space (EHDS). RWE solutions, encompassing curated health datasets and advanced consulting and analytics services, are increasingly essential for life sciences companies, payers, and providers seeking to understand treatment performance in real-world European clinical settings.
 

• The European RWE solutions market is projected to grow at a CAGR of 11.4% from 2026 to 2036, driven by mandatory EU Joint Clinical Assessments (JCA) under HTA Regulation 2021/2282, increasing EHR digitalization across member states, and growing pharmaceutical demand for market access evidence.
• By revenue, the European RWE solutions market is expected to reach around USD 2.5 billion by 2036.
• Germany is expected to be the largest national market for RWE solutions in Europe in 2026, driven by its large pharmaceutical and biotechnology sector, statutory health insurance (GKV) data infrastructure, and the DVPMG digitalization act.
• A key driver of market growth is the EU HTA Regulation 2021/2282, which mandates Joint Clinical Assessments for oncology medicines and Advanced Therapy Medicinal Products (ATMPs) from January 2025, compelling manufacturers to generate high-quality comparative real-world evidence for pan-European market access submissions.
• By component, the Datasets segment is expected to hold the largest share of the European RWE solutions market in 2026, driven by the foundational role of curated electronic health records, claims data, and patient registry data as the raw material for evidence generation across drug development and market access workflows.
• The Consulting & Analytics segment is expected to grow at the fastest CAGR during the forecast period, driven by increasing outsourcing of complex comparative effectiveness research, health economic modeling, and GDPR-compliant study design services by European pharmaceutical and biotech companies.
• By application, the Market Access & Reimbursement/Coverage Decisions segment is expected to hold the largest share of the European market in 2026, with the stringent real-world evidence requirements imposed by European HTA bodies such as NICE (U.K.), G-BA/IQWiG (Germany), HAS (France), and AIFA (Italy).
• By end user, the Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to hold the largest share of the European market in 2026.
• A major challenge in the European market is ensuring cross-border data interoperability and GDPR compliance when aggregating patient-level health data from heterogeneous national health systems for pan-European RWE studies.

Real-world evidence (RWE) solutions convert real-world data (RWD) derived from sources such as electronic health records, administrative claims databases, patient registries, and genomic datasets into actionable clinical and economic evidence to support regulatory submissions, market access decisions, pharmacovigilance, and health technology assessment (HTA) processes across European healthcare systems.
 

The European RWE solutions market is shaped by a dual regulatory environment comprising centralized EU-level regulatory frameworks and decentralized national-level HTA and reimbursement systems. While the European Medicines Agency (EMA) increasingly recognizes the role of RWE in supporting post-authorization safety monitoring, label extensions, and conditional approvals, national HTA bodies across member states continue to require country-specific comparative effectiveness and outcomes data to inform pricing and reimbursement decisions. This has led to growing demand for RWE solutions capable of generating both pan-European and localized evidence packages.
 

The ongoing digitalization of European healthcare infrastructure is expanding the availability of structured real-world data for research and regulatory use. National digital health platforms such as NHS Digital in the U.K., the Système National des Données de Santé (SNDS) in France, the Telematikinfrastruktur in Germany, and the Fascicolo Sanitario Elettronico in Italy are generating large-scale longitudinal patient datasets with increasing accessibility for observational research. In addition, Nordic countries, including Sweden, Denmark, Finland, and Norway, maintain population-level health registries with extensive longitudinal follow-up and robust data linkage capabilities, supporting their widespread use in pharmacoepidemiology and outcomes-based research.
 

The EMA’s Data Analysis and Real World Interrogation Network (DARWIN EU), a federated network of real-world data sources established to support regulatory decision-making, reflects the growing institutionalization of RWE within the European medicines regulatory framework and is expected to further support demand for advanced RWE analytics and evidence-generation solutions across the region.

Implementation of EU Joint Clinical Assessment Increasing Demand for Standardized Comparative Evidence

A key trend in the European RWE solutions market is the implementation of the Joint Clinical Assessment (JCA) framework under EU HTA Regulation (EU) 2021/2282, which became applicable to oncology medicines and advanced therapy medicinal products (ATMPs) in January 2025. The JCA introduces a centralized EU-level assessment of the relative clinical effectiveness of selected medicinal products, requiring pharmaceutical manufacturers to submit harmonized comparative clinical evidence for evaluation by participating member states. While real-world evidence (RWE) is not mandated, it is increasingly utilized to complement clinical trial data, particularly in the context of indirect treatment comparisons, long-term effectiveness, and population subgroup analyses. As the scope of JCA expands to additional therapeutic areas in subsequent implementation phases, demand for RWE solutions capable of supporting standardized comparative effectiveness assessments across multiple jurisdictions is expected to increase.

Increasing Adoption of Federated Data Networks to Enable GDPR-Compliant Pan-European Studies

The growing adoption of federated data network models is another key operational trend in the European RWE solutions market, driven by the need to comply with the General Data Protection Regulation (GDPR) governing cross-border processing of personal health data. Federated analytics approaches allow study algorithms to be executed locally within participating data environments, enabling multi-country analyses without requiring the transfer of patient-level data to a centralized repository. Initiatives such as the European Medicines Agency’s Data Analysis and Real World Interrogation Network (DARWIN EU) and EU-funded collaborative research infrastructures illustrate the increasing adoption of federated analytics approaches across European real-world data ecosystems. The increasing use of federated data architectures is expected to support the generation of methodologically robust, GDPR-compliant RWE for regulatory and HTA applications across European healthcare systems.

Which Component Holds the Largest Share in 2026, and Which is Expected to Grow at the Fastest CAGR?

In 2026, the Datasets segment is expected to account for the largest share of the European RWE solutions market. The established health data infrastructure, including longitudinal electronic health records (EHRs), statutory health insurance claims databases, and population-level disease registries in Europe, provides a robust foundation for observational research. For instance, national health registries across Nordic countries collectively provide longitudinal coverage for over 27 million individuals, with linkage across hospital admissions, prescription use, and mortality data routinely used in pharmacoepidemiological research (Nordic Medico-Statistical Committee). In addition, the European Health Data & Evidence Network (EHDEN) has mapped over 500 million patient records into a common data model to support multi-country real-world studies.

Meanwhile, the Consulting & Analytics segment is expected to grow at the fastest CAGR during the forecast period from 2026 to 2036. Increasing methodological complexity in multi-country RWE study design, alongside evolving HTA evidence expectations under the EU HTA Regulation (EU) 2021/2282 and GDPR-compliant data governance requirements, is driving the outsourcing of analytical and strategic consulting services. Providers offering integrated capabilities in comparative effectiveness research, health economic modeling, and HTA submission support are expected to experience accelerated growth in this segment.

Which Application Holds the Largest Share in 2026, and Which is Expected to Grow at the Fastest CAGR?

In 2026, the Market Access & Reimbursement / Coverage Decisions segment is expected to hold the largest share of the European RWE solutions market. More than 80% of newly authorized medicines in the EU are subject to national-level health technology assessment (HTA) prior to reimbursement approval (European Commission), requiring manufacturers to provide robust comparative clinical and economic evidence to support pricing and coverage decisions. Real-world evidence is increasingly utilized to complement clinical trial data in the evaluation of treatment effectiveness in routine clinical practice, supporting outcomes-based reimbursement and managed entry agreements across European healthcare systems.

Conversely, the Post-Market Surveillance & Pharmacovigilance segment is expected to grow at the fastest CAGR through 2036. This growth is driven by regulatory requirements under EU Good Pharmacovigilance Practices (GVP) Module VIII for post-authorization safety studies (PASS). As of recent EMA reporting, over 300 PASS studies are currently registered in the EU PAS Register, showing the increasing role of real-world data in long-term safety monitoring and regulatory commitments.

Which End User Holds the Largest Share in 2026, and Which is Expected to Grow at the Fastest CAGR?

In 2026, the Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to account for the largest share of the European RWE solutions market, driven by the need to generate evidence for EMA regulatory submissions, national HTA dossiers, and post-authorization commitments. The concentration of global pharmaceutical and emerging biotechnology firms across major European markets, including Germany, the U.K., Switzerland, Belgium, and the Netherlands, further drive demand for RWE datasets and analytical services.

The Healthcare Payers & HTA Bodies segment is expected to grow at the fastest CAGR during the forecast period, as national health insurance systems and HTA agencies increasingly invest in internal RWE capabilities to independently assess manufacturer-submitted evidence and support evidence-based coverage decision-making.